Taxotere Docetaxel Injection

1. Indications and Usage
Breast Cancer: Treatment of locally advanced or metastatic breast cancer after failure of prior chemotherapy.
Non-Small Cell Lung Cancer (NSCLC): Treatment of locally advanced or metastatic NSCLC after failure of prior platinum-based chemotherapy.
Prostate Cancer: Treatment of hormone-refractory metastatic prostate cancer in combination with prednisone or prednisolone.
Gastric Cancer: Treatment of advanced gastric cancer or gastroesophageal junction adenocarcinoma in combination with cisplatin and fluoropyrimidine.
Head and Neck Cancer: Treatment of locally advanced or metastatic squamous cell carcinoma of the head and neck in combination with cisplatin and fluorouracil.
2. Dosage and Administration
Standard Regimen: 75 mg/m² administered intravenously over 1 hour once every 3 weeks.
Premedication: All patients must receive a premedication regimen of oral corticosteroids (e.g., dexamethasone 16 mg daily for 3 days, starting 1 day prior to Docetaxel administration) to prevent fluid retention and hypersensitivity reactions.
Dose Adjustments: Dosage must be reduced if severe neutropenia (absolute neutrophil count <500/mm³ for ≥5 days) or severe non-hematologic toxicity occurs.
Administration: Dilute in 0.9% Sodium Chloride or 5% Glucose Injection to a final concentration not exceeding 0.74 mg/mL. Do not use PVC containers.
3. Mechanism of Action
Microtubule Stabilization: Docetaxel binds with high affinity to free and polymerized tubulin, promoting tubulin assembly into microtubules while inhibiting disassembly.
Cell Cycle Arrest: This stabilization leads to the inhibition of microtubule dynamics required for fundamental mitotic and interphase cellular functions, arresting cells in the G2 and M phases and ultimately causing cell death.
4. Safety and Warnings
Severe Neutropenia: The most common severe toxicity; monitor absolute neutrophil counts closely. Febrile neutropenia and sepsis are serious risks.
Fluid Retention: Can progress to peripheral edema, pleural effusion, or ascites. Pre-medication with corticosteroids is mandatory to mitigate this risk.
Hypersensitivity Reactions: Severe reactions including hypotension and bronchospasm may occur; immediate medical intervention is required if they happen.
Hepatotoxicity: Severe liver injury can occur; dosage adjustments are necessary for patients with elevated bilirubin or alkaline phosphatase.
5. Adverse Reactions and Clinical Research
Common: Neutropenia, alopecia, nausea, vomiting, diarrhea, asthenia, and rash.
Serious: Febrile neutropenia, septic shock, severe fluid retention, and pulmonary edema.
Clinical Research: Clinical trials have demonstrated significant clinical benefit in overall survival and response rates when used in combination regimens for breast, lung, and prostate cancers.
6. Drug Interactions
CYP3A4 Inhibitors: Strong inhibitors (e.g., ketoconazole, erythromycin, cyclosporine) may interfere with Docetaxel metabolism and increase toxicity.
CYP3A4 Inducers: Strong inducers (e.g., phenytoin, carbamazepine, rifampin) may decrease Docetaxel exposure and therapeutic effect.
Other Myelosuppressive Agents: Concomitant use with other agents causing bone marrow suppression requires careful monitoring.
7. Pharmaceutical Information
Active Ingredient: Docetaxel.
Appearance: Pale orange to yellow clear liquid.
Storage: Store at 2-8°C. Protect from light.
Excipients: Citric acid, polysorbate 80, and anhydrous ethanol.